

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA TRADITIONAL CHINESE MEDICINE CO. LIMITED

中國中藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 570)

POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to the provisions of inside information (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Listing Rules.

The Board wishes to inform the Shareholders and potential investors that based on the preliminary assessment by the Company's management with reference to the unaudited consolidated management accounts of the Group for the six months ended June 30, 2014, the Group is expected to record a significant increase in consolidated net profit attributable to the Shareholders for the six months ended June 30, 2014 as compared with the consolidated net profit attributable to the Shareholders of approximately HK\$78.5 million for the six months ended June 30, 2013.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by China Traditional Chinese Medicine Co. Limited (the "**Company**") and together with its subsidiaries, the "**Group**") pursuant to the provisions of inside information (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) under Part XIVA of the Securities and Futures Ordinance (Cap. 571) and Rule 13.09 of the Listing Rules.

The board of directors (the "**Board**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on the preliminary assessment by the Company's management with reference to the unaudited consolidated management accounts of the Group for the six months ended June 30, 2014, the Group is expected to record a significant increase in consolidated net profit attributable to the Shareholders for the six months ended June 30, 2014 as compared with the consolidated net profit attributable to the Shareholders of approximately HK\$78.5 million for the six months ended June 30, 2013.

The Board considers that the expected improvement in the overall results of the Group for the six months ended June 30, 2014 as compared with the corresponding period in 2013 was mainly attributable to the consolidation of the financial results of Tongjitang Chinese Medicines Company (which was acquired by the Company in October 2013) and its subsidiaries.

The information contained in this announcement is only based on the Board's preliminary assessment with reference to the unaudited consolidated management accounts of the Group and is not based on any financial data or information that has been audited or reviewed by the Company's independent auditor. The Company is in the process of finalising the interim results of the Group for the six months ended June 30, 2014. Details of the financial data to be disclosed in the Company's interim report for the six months ended June 30, 2014 shall prevail.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Traditional Chinese Medicine Co. Limited
WU Xian
Chairman

Hong Kong, 7 July 2014

As at the date of this announcement, the Board comprises 11 directors, of which Mr. WU Xian, Mr. YANG Bin and Mr. WANG Xiaochun are executive Directors; Mr. SHE Lulin, Mr. LIU Cunzhou, Mr. DONG Zenghe and Mr. ZHAO Dongji are non-executive Directors; and Mr. ZHOU Bajun, Mr. XIE Rong, Mr. FANG Shuting and Mr. YU Tze Shan Hailson are independent non-executive Directors.